• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导多能干细胞作为治疗糖尿病的一种潜在方法。

Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes.

机构信息

Department of Surgery, University of Alberta, Edmonton, AB T6G 2B7, Canada.

Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada.

出版信息

Cells. 2021 Jan 30;10(2):278. doi: 10.3390/cells10020278.

DOI:10.3390/cells10020278
PMID:33573247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7911560/
Abstract

Over the last century, diabetes has been treated with subcutaneous insulin, a discovery that enabled patients to forego death from hyperglycemia. Despite novel insulin formulations, patients with diabetes continue to suffer morbidity and mortality with unsustainable costs to the health care system. Continuous glucose monitoring, wearable insulin pumps, and closed-loop artificial pancreas systems represent an advance, but still fail to recreate physiologic euglycemia and are not universally available. Islet cell transplantation has evolved into a successful modality for treating a subset of patients with 'brittle' diabetes but is limited by organ donor supply and immunosuppression requirements. A novel approach involves generating autologous or immune-protected islet cells for transplant from inducible pluripotent stem cells to eliminate detrimental immune responses and organ supply limitations. In this review, we briefly discuss novel mechanisms for subcutaneous insulin delivery and define their shortfalls. We describe embryological development and physiology of islets to better understand their role in glycemic control and, finally, discuss cell-based therapies for diabetes and barriers to widespread use. In response to these barriers, we present the promise of stem cell therapy, and review the current gaps requiring solutions to enable widespread use of stem cells as a potential cure for diabetes.

摘要

在过去的一个世纪里,糖尿病一直采用皮下胰岛素治疗,这一发现使患者免于因高血糖而死亡。尽管有新的胰岛素制剂,但糖尿病患者仍面临发病率和死亡率,给医疗保健系统带来了不可持续的成本。连续血糖监测、可穿戴胰岛素泵和闭环人工胰腺系统是一种进步,但仍未能重现生理性的正常血糖水平,并且并非普遍可用。胰岛细胞移植已发展成为治疗“脆性”糖尿病患者的一种成功方法,但受到供体器官供应和免疫抑制需求的限制。一种新方法涉及从诱导多能干细胞生成自体或免疫保护的胰岛细胞用于移植,以消除有害的免疫反应和器官供应限制。在这篇综述中,我们简要讨论了皮下胰岛素输送的新机制,并定义了它们的不足。我们描述了胰岛的胚胎发育和生理学,以更好地理解它们在血糖控制中的作用,最后讨论了用于糖尿病的基于细胞的治疗方法和广泛应用的障碍。针对这些障碍,我们提出了干细胞治疗的前景,并回顾了目前需要解决的差距,以实现干细胞的广泛应用,作为糖尿病的一种潜在治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/dfe44d46976f/cells-10-00278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/16eab7c17a2c/cells-10-00278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/9740566dcfe6/cells-10-00278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/59f77ff3bdfb/cells-10-00278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/78073975b584/cells-10-00278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/dfe44d46976f/cells-10-00278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/16eab7c17a2c/cells-10-00278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/9740566dcfe6/cells-10-00278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/59f77ff3bdfb/cells-10-00278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/78073975b584/cells-10-00278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4147/7911560/dfe44d46976f/cells-10-00278-g005.jpg

相似文献

1
Inducible Pluripotent Stem Cells as a Potential Cure for Diabetes.诱导多能干细胞作为治疗糖尿病的一种潜在方法。
Cells. 2021 Jan 30;10(2):278. doi: 10.3390/cells10020278.
2
Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead.人类诱导多能干细胞在糖尿病治疗中的应用及潜在障碍
Adv Exp Med Biol. 2019;1144:25-35. doi: 10.1007/5584_2018_305.
3
Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes.干细胞衍生胰岛细胞治疗糖尿病的免疫保护。
Front Endocrinol (Lausanne). 2021 Aug 10;12:716625. doi: 10.3389/fendo.2021.716625. eCollection 2021.
4
Current Status, Barriers, and Future Directions for Humanized Mouse Models to Evaluate Stem Cell-Based Islet Cell Transplant.用于评估基于干细胞的胰岛细胞移植的人源化小鼠模型的现状、障碍和未来方向。
Adv Exp Med Biol. 2022;1387:89-106. doi: 10.1007/5584_2022_711.
5
Durable Control of Autoimmune Diabetes in Mice Achieved by Intraperitoneal Transplantation of "Neo-Islets," Three-Dimensional Aggregates of Allogeneic Islet and "Mesenchymal Stem Cells".通过向腹腔内移植“新胰岛”(同种异体胰岛和“间充质干细胞”的三维聚集体),实现对小鼠自身免疫性糖尿病的持久控制。
Stem Cells Transl Med. 2017 Jul;6(7):1631-1643. doi: 10.1002/sctm.17-0005. Epub 2017 May 3.
6
A Stem Cell Approach to Cure Type 1 Diabetes.干细胞方法治疗 1 型糖尿病。
Cold Spring Harb Perspect Biol. 2021 Jan 4;13(1):a035741. doi: 10.1101/cshperspect.a035741.
7
Differentiation of human pluripotent stem cells into β-cells: Potential and challenges.人类多能干细胞向β细胞的分化:潜力与挑战。
Best Pract Res Clin Endocrinol Metab. 2015 Dec;29(6):833-47. doi: 10.1016/j.beem.2015.10.011. Epub 2015 Oct 30.
8
Optimizing Generation of Stem Cell-Derived Islet Cells.优化干细胞衍生胰岛细胞的生成。
Stem Cell Rev Rep. 2022 Dec;18(8):2683-2698. doi: 10.1007/s12015-022-10391-3. Epub 2022 May 31.
9
The Current Status of Allogenic Islet Cell Transplantation.同种异体胰岛细胞移植的现状。
Cells. 2023 Oct 10;12(20):2423. doi: 10.3390/cells12202423.
10
Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.干细胞疗法正成为治疗1型糖尿病的关键手段。
Cytotherapy. 2016 Sep;18(9):1077-86. doi: 10.1016/j.jcyt.2016.06.006. Epub 2016 Jul 14.

引用本文的文献

1
Medical embryology and regenerative medicine: research and applications in clinical practice.医学胚胎学与再生医学:临床实践中的研究与应用
Front Cell Dev Biol. 2025 Aug 26;13:1619036. doi: 10.3389/fcell.2025.1619036. eCollection 2025.
2
Advanced therapy to cure diabetes: mission impossible is now possible?治愈糖尿病的先进疗法:“不可能完成的任务”现在有可能实现吗?
Front Cell Dev Biol. 2024 Nov 19;12:1484859. doi: 10.3389/fcell.2024.1484859. eCollection 2024.
3
Identification and removal of unexpected proliferative off-target cells emerging after iPSC-derived pancreatic islet cell implantation.

本文引用的文献

1
Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes.PD-1/PD-L1 二聚体在维持胰腺免疫耐受以预防 1 型糖尿病中的作用。
Front Endocrinol (Lausanne). 2020 Aug 19;11:569. doi: 10.3389/fendo.2020.00569. eCollection 2020.
2
Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis.全球1型糖尿病的患病率和发病率:一项系统评价与荟萃分析。
Health Promot Perspect. 2020 Mar 30;10(2):98-115. doi: 10.34172/hpp.2020.18. eCollection 2020.
3
A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells.
鉴定和去除 iPSC 衍生胰岛细胞移植后出现的意外增殖性非靶细胞。
Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2320883121. doi: 10.1073/pnas.2320883121. Epub 2024 Apr 10.
4
Mitochondrial regulation in human pluripotent stem cells during reprogramming and β cell differentiation.人多能干细胞重编程及β细胞分化过程中线粒体调控。
Front Endocrinol (Lausanne). 2023 Oct 20;14:1236472. doi: 10.3389/fendo.2023.1236472. eCollection 2023.
5
Unlocking the post-transplant microenvironment for successful islet function and survival.解锁移植后微环境以实现胰岛功能和存活的成功。
Front Endocrinol (Lausanne). 2023 Aug 29;14:1250126. doi: 10.3389/fendo.2023.1250126. eCollection 2023.
6
Establishment and characterization of a novel human induced pluripotent stem cell line stably expressing the iRFP720 reporter.建立并鉴定一株新型稳定表达 iRFP720 报告基因的人诱导多能干细胞系。
Sci Rep. 2022 Jun 14;12(1):9874. doi: 10.1038/s41598-022-12956-1.
7
Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC.从人诱导多能干细胞分化而来的胰岛样内分泌细胞相关的非内分泌细胞的鉴定和减少。
Sci Rep. 2022 Mar 18;12(1):4740. doi: 10.1038/s41598-022-08753-5.
8
Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies.生成人胰腺类器官:细胞来源、生物材料和三维技术的进展。
Theranostics. 2022 Jan 3;12(4):1537-1556. doi: 10.7150/thno.66670. eCollection 2022.
9
Study on the TCM Syndromes Evolution and Chinese Herbal Characteristics of Type 2 Diabetes Patients with Different Courses of Disease in TCM "Heat Stage": A Real-World Study.中医“热盛期”2型糖尿病不同病程患者中医证候演变及用药特点研究:一项真实世界研究
Evid Based Complement Alternat Med. 2021 Jun 16;2021:1282957. doi: 10.1155/2021/1282957. eCollection 2021.
用于长期包封和存活治疗性异种细胞的可回收植入物。
Nat Biomed Eng. 2020 Aug;4(8):814-826. doi: 10.1038/s41551-020-0538-5. Epub 2020 Mar 30.
4
Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells.靶向细胞骨架以指导人多能干细胞的胰腺分化。
Nat Biotechnol. 2020 Apr;38(4):460-470. doi: 10.1038/s41587-020-0430-6. Epub 2020 Feb 24.
5
Reduced pancreatic polypeptide response is associated with early alteration of glycemic control in chronic pancreatitis.慢性胰腺炎患者的血糖控制早期改变与胰腺多肽反应降低有关。
Diabetes Res Clin Pract. 2020 Feb;160:107993. doi: 10.1016/j.diabres.2019.107993. Epub 2019 Dec 23.
6
Generation of hypoimmunogenic human pluripotent stem cells.生成低免疫原性的人类多能干细胞。
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10441-10446. doi: 10.1073/pnas.1902566116. Epub 2019 Apr 30.
7
Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques.藻酸盐封装作为对移植到猕猴网膜囊中的同种异体胰岛细胞的长期免疫保护。
Nat Biomed Eng. 2018 Nov;2(11):810-821. doi: 10.1038/s41551-018-0275-1. Epub 2018 Aug 13.
8
Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy.在糖尿病中实现血糖正常化的两条道路:自动化胰岛素输送装置和细胞疗法。
Cell Metab. 2019 Mar 5;29(3):545-563. doi: 10.1016/j.cmet.2019.02.007.
9
β Cell tone is defined by proglucagon peptides through cAMP signaling.β 细胞的功能状态由胰高血糖素原肽通过 cAMP 信号通路来定义。
JCI Insight. 2019 Mar 7;4(5). doi: 10.1172/jci.insight.126742.
10
Biomaterials: Foreign Bodies or Tuners for the Immune Response?生物材料:免疫反应的异物还是调谐器?
Int J Mol Sci. 2019 Feb 1;20(3):636. doi: 10.3390/ijms20030636.